These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 10688729

  • 1. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent.
    Katz KH, Marks JG, Helm KF.
    J Am Acad Dermatol; 2000 Mar; 42(3):514-5. PubMed ID: 10688729
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
    Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghans V, Luger TA.
    Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
    [Abstract] [Full Text] [Related]

  • 5. Treatment of pemphigus vulgaris with mycophenolate mofetil.
    Enk AH, Knop J.
    Lancet; 1997 Aug 16; 350(9076):494. PubMed ID: 9274594
    [No Abstract] [Full Text] [Related]

  • 6. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus.
    Williams JV, Marks JG, Billingsley EM.
    Br J Dermatol; 2000 Mar 16; 142(3):506-8. PubMed ID: 10735959
    [Abstract] [Full Text] [Related]

  • 7. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
    Esmaili N, Chams-Davatchi C, Valikhani M, Farshidfar F, Parvaneh N, Tamizifar B.
    Eur J Dermatol; 2008 Mar 16; 18(2):159-64. PubMed ID: 18424375
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.
    Koga H, Ishii N, Hamada T, Karashima T, Nakama T, Yasumoto S, Hashimoto T.
    Eur J Dermatol; 2010 Mar 16; 20(4):472-5. PubMed ID: 20406724
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.
    Doukaki S, Pistone G, Aricò M, Bongiorno MR.
    Expert Opin Drug Metab Toxicol; 2011 Feb 16; 7(2):237-44. PubMed ID: 21192770
    [Abstract] [Full Text] [Related]

  • 10. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil.
    Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC.
    Arch Dermatol; 2003 Jun 16; 139(6):739-42. PubMed ID: 12810504
    [Abstract] [Full Text] [Related]

  • 11. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.
    Megahed M, Schmiedeberg S, Becker J, Ruzicka T.
    J Am Acad Dermatol; 2001 Aug 16; 45(2):256-9. PubMed ID: 11464188
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
    Vyas N, Patel NS, Cohen GF.
    J Drugs Dermatol; 2013 Feb 16; 12(2):210-6. PubMed ID: 23377396
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris.
    Baskan EB, Yilmaz M, Tunali S, Saricaoglu H.
    J Eur Acad Dermatol Venereol; 2009 Dec 16; 23(12):1432-4. PubMed ID: 19470052
    [Abstract] [Full Text] [Related]

  • 14. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.
    Schütz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M.
    Clin Chem; 1999 Mar 16; 45(3):419-22. PubMed ID: 10053049
    [No Abstract] [Full Text] [Related]

  • 15. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
    Biot Sdel R, Franco JP, Lima RB, Pereira HN, Marques LP, Martins CJ.
    An Bras Dermatol; 2014 Mar 16; 89(6):980-4. PubMed ID: 25387507
    [Abstract] [Full Text] [Related]

  • 16. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study.
    De Simone C, Caldarola G, Perino F, Venier A, Guerriero G.
    Dermatol Ther; 2012 Mar 16; 25(2):219-22. PubMed ID: 22741942
    [Abstract] [Full Text] [Related]

  • 17. A rare cause of unilateral facial rash.
    Krase IZ, Wickenheiser M, Chao J, Kurtzman D, Segal R, Culpepper K, Shi V.
    Clin Exp Dermatol; 2019 Jun 16; 44(4):425-427. PubMed ID: 30229995
    [No Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil, Crohn's disease, measles?
    Altschuler EL.
    Am J Gastroenterol; 2000 Feb 16; 95(2):550-1. PubMed ID: 10685769
    [No Abstract] [Full Text] [Related]

  • 19. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P, Hambach P, Braun KP, Fritsche L, Waiser J, Mai I, Neumayer HH, Budde K.
    Int J Clin Pharmacol Ther; 2003 Oct 16; 41(10):470-6. PubMed ID: 14703953
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study.
    Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D.
    J Eur Acad Dermatol Venereol; 2012 Jul 16; 26(7):855-60. PubMed ID: 21752101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.